“The Food and Drug Administration on Tuesday told Eli Lilly and Novo Nordisk to remove warnings about the risk of suicidal thoughts and behavior from the labels of their blockbuster GLP-1 weight-loss drugs.

Why it matters: The action caps more than a year of studies into reported side effects in people taking the injectable drugs. It covers Novo Nordisk’s Saxenda and Wegovy and Lilly’s Zepbound.

Some research has focused on patients with psychiatric disorders, since certain antipsychotics or antidepressants are associated with weight gain and could make the patients possible candidates for GLP-1 treatment.

Driving the news: Regulators said a comprehensive review found no increased risk of suicidal ideation or behavior associated with the use of GLP-1s.”

From Axios.